Your SlideShare is downloading. ×
0
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C

470

Published on

Janin speaks on the dawn of a revolution for treating Hepatitis C. This was recorded at Bedside Critical Care Conference 4. Full postings can be found at www.intensivecarenetwork.com

Janin speaks on the dawn of a revolution for treating Hepatitis C. This was recorded at Bedside Critical Care Conference 4. Full postings can be found at www.intensivecarenetwork.com

Published in: Health & Medicine
0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
470
On Slideshare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
25
Comments
0
Likes
2
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  1. Dawn of a revolution P. Janin RNSH – ICU 26.09.2013
  2.  1965 - Blumberg & Alter  1973 – Feinstone, Kapikian & Purcell The hepatitis puzzle was still incomplete
  3. …. ….
  4.  Part of Flaviviridae family of viruses  Associated with both human and animal disease  3 genera: pestiviruses (cattle, pigs), flaviviruses (dengue, yellow fever), hepaciviruses (HCV)  In hepacivirus family  6 major clades  >100 different subtypes  Countless quasispecies: mult. seen in each infected individual
  5. Study of Infection, Replication and Release Difficult:  Lack of reliable culture system  Does not integrate into host genome  Low number of circulating virions
  6. Structural genes Non-structural genes
  7. Pathogenesis Prevention Therapy
  8.  Complex, dynamic distributions of non-identical but related mutant RNA genomes  Encompasses a master genome (dominant) and a multitude of minor genomes
  9. Escapes host immune surveillance ? Establishes persistent infection ?
  10. Exposure (Acute Phase) Resolved Chronic CirrhosisStable Liver Decompensation Hepatocellular Carcinoma 5%-25% over 20-30 years 15-45% 55-85% 5%/yr decompensation 2-8%/yr HCC 75-95% Primary Point of Intervention  Acute Hepatitis C  Generally benign:  No jaundice (80%). Usually asymptomatic.  Can be severe, but liver failure rare  15-40% will usually resolve.
  11.  Only real threat of acute Hepatitis C is its ability to reach chronic stages undetected and untreated.
  12. 90% 5-10% 80-90% 70-85% 2% (coinfection) 90% (superinfection)  Infants  Adults Normal liver Chronic hepatitis Cirrhosis
  13.  3.2 million persons chronically infected (average age 55 years, perhaps 40% have cirrhosis)  8000-10.000 deaths each year (US)  Majority unaware of infection: not clinically ill (only 25-30% have been diagnosed, only 11% have been treated)
  14.  221.000 people with chronic hepatitis C  Leading reason for liver transplant  Deaths have surpassed HIV HIV HCV
  15. Indirect Serological assays Direct Virological assays Commercial HCV Assays Antibody assays EIA-III RIBA-III HCV RNA detection - Qualitative - Quantitative Molecular HCV genotyping There is a seronegative window in which HCV RNA is the only marker that permits the diagnosis of primary HCV infection and the identification of potentially infectious patients that would be missed by conventional antibody testing
  16.  Genetic heterogeneity  High rate of viral persistence  Lack of solid immunity  Poor definition of protection correlates  Technical limitations in the study of HCV
  17.  Viral eradication  SVR = cure  Arrest progression of necrosis/fibrosis  Reduce progression of fibrosis/cirrhosis  Prevent decompensation  Prevent HCC Primary objectives Secondary objectives SVR: Sustained Virological Response
  18.  SVR is defined as absence of HCV RNA in the serum at the end of treatment and 6 months later  Patients who achieve an SVR may be deemed clinically cured of chronic HCV
  19. ~1990’s mid-90’s ~2000-01
  20. Peginterferon alfa-2a (40KD) Ribavirin SC injection, once weekly By mouth, twice daily  Direct inhibition of HCV RNA- dependent RNA polymerase ? RNA mutagenesis ?  Depletion of intracellular GTP pools via IMPDH inhibition ?  T-cell enhancement  OAS: activates antiviral RNAses  PKR: inactivates viral ptn translation  ADA: edits viral RNA
  21. 30-40% 80%
  22. RVR RapidVirologic Response HCV RNA negative at 4 weeks (< 50 IU/mL) EVR EarlyVirologic Response HCV RNA negative or > 2 log10 drop at week 12. cEVR (complete) or pEVR (partial) SVR Sustained Virologic Response HCV RNA negative 24 weeks after end of treatment Relapse HCV RNA negative at end of treatment but HCV RNA positive after treatment stopped
  23.  Previously, treatment recommendation was based on the HCV genotype  The early kinetics of HCV viremia (week 4) are emerging as the most reliable predictive marker of response  Quantification of HCV viremia is essential for tailoring the treatment schedule: Response Guided Therapy
  24.  Favorable  Genotype 2 and 3  HCV RNA < 400,000 IU/ml  Mild fibrosis (F0-F2)  Age < 40  IL28B CC  Adherence  RVR and cEVR  Unfavorable  Genotype 1  HCV RNA > 400,000 IU/ml  Advanced fibrosis (F3-F4)  Age > 40  Steatosis, Insulin Resistance, high BMI  IL28B CT or TT  Dose reduction > 60%  Non-adherence
  25. Side effects  Flu-like symptoms  Weight loss  Depression  Neutropenia  Concentration/memory disturbance  Insomnia  Thrombocytopenia
  26. Side effects  Haemolytic anaemia  Significant teratogenicity  Rash  Fatigue  Itching  Sinusitis
  27. Log(10)HCVRNAIU/ml Days 8 6 4 2 14 Telaprevir 100 Peginterferon + Ribavirin Telaprevir + Peg/RBV
  28.  Are added to (do not replace) original therapy.  Indications:  treatment of chronic Hep C (genotype 1).  with compensated liver disease, including cirrhosis.  previously untreated or who have failed previous interferon and ribavirin therapy.
  29. Telaprevir (GT1) (ADVANCE & REALIZE trials) Boceprevir (GT1) (SPRINT2 & RESPOND2) %SVR
  30. Mono infected  GT 2,3: pegIFN + RBV x 24wk  GT 4: x 48wk  GT 1: pegIFN + RBV + DAA  Variable duration based on response (24, 36, or 48 wk)
  31. Telaprevir Time point HCV RNA Action Week 4 or 12 > 1000 IU/mL Stop T/P/R Week 24 Detectable Stop P/R Boceprevir Time point HCV RNA Action Week 8 or 12 > 100 IU/mL Stop B/P/R Week 24 Detectable Stop P/R
  32. Telaprevir DAA/P/R P/R Pruritis 45-50% 28% Nausea 40-43% 31% Rash 56% 34% Anemia 37-39% 19% Diarrhea 28-32% 17% Anorectal discomfort 11% 3% Boceprevir Anemia 50% 30% Dysgeusia 35-43% 16% Neutropenia 25% 19% Nausea 46% 42%
  33.  Wave 1 (2011-2014): add-on Rx  1st generation PIs + SOC: naïve and experienced  Wave 2 (2014-2016): the better mousetrap  Substitution of 2nd generation PIs (better barrier to resistance, tolerance), Nucs (better PK, tolerability)  Substitution of better tolerated IFNs  4 drug regimens for P/R/PI failures (quad therapy)  Wave 3 (2015-2020): the holy grail  Oral cocktails of DAAs, host cofactor inhibitors, RBV  IFN-free regimen!
  34.  Improved efficacy ?
  35.  NEUTRINO study (Phase III registration trial)  AE in >20%
  36.  Strong barrier to resistance !
  37.  For GT 1  No anemia and no grade 3-4 AE
  38.  For GT 2 and 3
  39.  DCV (PI) + SOF (Nuc-PoI) in Boceprevir/PR failures.
  40.  Genotype 1:  PEG / RBV + Simeprevir (2nd gen PI)  PEG / RBV + Sofosbuvir (PoI)  Genotype 2, 3:  RBV + Sofosbuvir  Off label combination of available DAA classes  Simeprevir + Sofosbuvir + RBV for GT1
  41.  Emerging DAA therapy against 3 major viral proteins will provide solutions for most patients with HCV.  Strong potency  Nonoverlapping resistance profile  Enough genotypic / subgenotypic range  High barriers compounds desirable for simplified regimens. Can be matched by combinations of DAA classes.  Novel host targets increasingly identified, including many involved in Lipid metabolism. Inherently high barrier to resistance.
  42.  Thank you. Printed material and product information available here !!

×